| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA5285794
Max Phase: Preclinical
Molecular Formula: C40H48NO10P
Molecular Weight: 733.79
Associated Items:
Representations
Canonical SMILES: CCOP(=O)(OCC)C(Nc1ccc(CC(=O)OCCOc2cc(/C=C\c3cc(OC)c(OC)c(OC)c3)ccc2OC)cc1)c1ccc(C)cc1
Standard InChI: InChI=1S/C40H48NO10P/c1-8-50-52(43,51-9-2)40(32-17-10-28(3)11-18-32)41-33-19-14-30(15-20-33)27-38(42)49-23-22-48-35-24-29(16-21-34(35)44-4)12-13-31-25-36(45-5)39(47-7)37(26-31)46-6/h10-21,24-26,40-41H,8-9,22-23,27H2,1-7H3/b13-12-
Standard InChI Key: XCHCPIMRHIXPAZ-SEYXRHQNSA-N
Associated Targets(Human)
HepG2 (196354 Activities)
HT-29 (80576 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
A549 (127892 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
MGC-803 (6426 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
L02 (4864 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
MMP2 Tchem Matrix metalloproteinase-2 (6627 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
MMP3 Tchem Matrix metalloproteinase 3 (3433 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
MMP9 Tchem Matrix metalloproteinase 9 (6779 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 733.79 | Molecular Weight (Monoisotopic): 733.3016 | AlogP: 8.74 | #Rotatable Bonds: 20 |
| Polar Surface Area: 120.01 | Molecular Species: NEUTRAL | HBA: 11 | HBD: 1 |
| #RO5 Violations: 3 | HBA (Lipinski): 11 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 3 |
| CX Acidic pKa: 12.64 | CX Basic pKa: 0.25 | CX LogP: 7.59 | CX LogD: 7.59 |
| Aromatic Rings: 4 | Heavy Atoms: 52 | QED Weighted: 0.04 | Np Likeness Score: -0.35 |
References
| 1. Huang X, Chen Y, Zhong W, Liu Z, Zhang H, Zhang B, Wang H.. (2022) Novel combretastatin A-4 derivative containing aminophosphonates as dual inhibitors of tubulin and matrix metalloproteinases for lung cancer treatment., 244 [PMID:36252396] [10.1016/j.ejmech.2022.114817] |
Source
Source(1):